Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE Operating Cash Flow
Cash generated by the company's core business operations during the period.
Pulse Biosciences, Inc.NASDAQ: PLSE
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow growth accelerates
Q2 FY2026 operating cash flow of $18.71M (cash outflow) rose 46.1% year over year, ahead of the +37.3% change in trailing-twelve-month operating cash flow. Sequentially, it rose 28.2% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Operating cash flow amounted to 15463.4% of revenue in FY2025.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +46.1% holds above the trailing-twelve-month pace of +37.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (54.12M) USD
- Year-over-year change
- -48.9%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (54.12M) | -48.9% |
| FY2024 | 2024-12-31 | (36.34M) | -10.0% |
| FY2023 | 2023-12-31 | (33.04M) | +29.7% |
| FY2022 | 2022-12-31 | (47.01M) | +13.1% |
| FY2021 | 2021-12-31 | (54.1M) | — |
Operating Cash Flow vs competitors
How PLSE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +37.3% is the 4th highest of 11, against a peer median of +20.6%.
- Operating cash flow amounts to 5155.9% of revenue for PLSE, versus a peer median of 76.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $233.79M USD | +26.4% | -11.8% | 428.3% | |
| LTM Mar 2026 | €184.13M EUR | +15.3% | — | 493.7% | |
| LTM Mar 2026 | $163.3M USD | -10.5% | +23.3% | 28.1% | |
| LTM Jun 2026 | $155.38M USD | +55.0% | +64.4% | 8160.5% | |
| LTM Jun 2026 | $127.78M USD | +69.1% | -0.6% | 2856.6% | |
| LTM Jan 2026 | $86.68M USD | +25.9% | — | 103.5% | |
| LTM Jun 2026 | $61.1M USD | +37.3% | +4.8% | 5155.9% | |
| LTM Mar 2026 | $54.78M USD | -2.4% | -5.4% | 49.7% | |
| LTM Apr 2026 | $50.19M USD | +329.4% | — | 17.3% | |
| LTM Mar 2026 | $26.88M USD | -11.7% | — | 4.0% | |
| LTM Mar 2026 | $5.66M USD | -63.2% | — | 2.6% | |
| Peer median (excluding PLSE) | — | +20.6% | -0.6% | 76.6% | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Depreciation & Amortization | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.6M | 5.19M | 7.18M | 13.59M | 21.46M |
| Change in Working Capital | (6.2M) | (3.72M) | 768K | 2.47M | (5.02M) |
| Accounts Receivables | (61K) | 20K | 109K | 48K | (274K) |
| Inventory | (5.82M) | (2.65M) | 0 | 0 | (136K) |
| Accounts Payables | 1.16M | (1.3M) | 263K | (201K) | 1.13M |
| Other Working Capital | (1.47M) | 221K | 396K | 2.63M | (5.74M) |
| Other Non-Cash Items | 13K | 8.66M | 13K | 6K | 1.15M |
| Operating Cash Flow | (54.1M) | (47.01M) | (33.04M) | (36.34M) | (54.12M) |
| Capital Expenditures | (437K) | (401K) | (121K) | (125K) | (315K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 8M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (20K) |
| Investing Cash Flow | 7.56M | (401K) | (121K) | (125K) | (335K) |
| Debt Repayment | 407K | 65M | 0 | 0 | 0 |
| Common Stock Issued | 56.7M | 14.86M | 16.39M | 59.65M | 17.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 62.51M | 75K | (6K) | 50.49M | 0 |
| Financing Cash Flow | 62.69M | 79.94M | 16.39M | 110.14M | 17.15M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.15M | 32.53M | (16.77M) | 73.67M | (37.3M) |
| Free Cash Flow | (54.53M) | (47.41M) | (33.16M) | (36.47M) | (54.44M) |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.